TONY Investment
VC Fund
Seoul, South Korea
TONY Investment is a Venture Capital that invests in companies of all stages, from startups to scale-ups.
- Total investments:
- 29
- Last investment:
- Lead investor:
- 7%
Last updated:
For AI agents: llms.txt
Industries TONY Investment invests in
Stages TONY Investment invests in
Countries TONY Investment invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
4 more contacts available
Round size
- Seed
- $3M–$15M
- Series A
- $2.9M–$63M
- Series B
- $4M–$22M
Investment Focus
Industry
- Biotechnology 5 (17%)
- Health Care 4 (14%)
- Manufacturing 4 (14%)
- Information Technology 4 (14%)
- Gaming 3 (10%)
Stage
- Series A 8 (28%)
- Series B 8 (28%)
- Seed 5 (17%)
- Series C 3 (10%)
- Venture - Series Unknown 2 (7%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Joowon Park
Managing Director
|
Managing Director | Total investments: 1 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Dnotitia
|
Dnotitia is a pioneering AI (Artificial Intelligence) company driving innovative value by integrating AI and data. Founded in October 2023, Dnotitia specializes in developing; Seahorse, a high-performance vector database powered by its proprietary Vector Data Processing Units (VDPU), and Mnemos, a cutting-edge service solution for Large LanguageModels (LLMs). The company also leads the development of sLMs (Small Language Models) and Retrieval-Augmented Generation (RAG) systems, crucial for advancing generative AI technologies and positioning itself at the forefront of AI technology. | $63.4M / Series A / Apr 21, 2026 | |
ActionPower
|
ActionPower is an AI-based startup company that offers speech recognition and natural language processing technology services. | $4.1M / Series B / Mar 05, 2026 | |
MOPLAT
|
MOPLAT designs and manufactures electronic components used in mobility devices for automobiles. | $9.8M / Series A / Apr 23, 2025 | |
Ubix Therapeutics
|
Ubix Therapeutics is a research and development company that develops anti-cancer drugs. | $17.7M / Series C / Dec 23, 2024 | |
|
Dnotitia
|
Dnotitia is a pioneering AI (Artificial Intelligence) company driving innovative value by integrating AI and data. Founded in October 2023, Dnotitia specializes in developing; Seahorse, a high-performance vector database powered by its proprietary Vector Data Processing Units (VDPU), and Mnemos, a cutting-edge service solution for Large LanguageModels (LLMs). The company also leads the development of sLMs (Small Language Models) and Retrieval-Augmented Generation (RAG) systems, crucial for advancing generative AI technologies and positioning itself at the forefront of AI technology. | $14.6M / Seed / Dec 10, 2024 | |
Korea Precision Materials Industry
|
Korea Precision Materials Industry is a manufacturer of next-generation composite materials used for weight reduction. | $7.6M / Series A / Oct 22, 2024 | |
XCENA
|
MetisX is a startup firm that develops intelligent memory and memory-centric computing architectures based on CXL. | $44M / Series A / May 13, 2024 | |
XCENA
|
XCENA is a semiconductor company that develops data-centric computing systems designed for AI and large-scale data processing environments. The company builds computational memory technology that combines high-capacity pooled DDR5 memory with near-data processing capabilities, allowing computation to occur closer to where data is stored. Its coreplatform is based on the Compute Express Link (CXL) standard, which enables memory expansion beyond traditional CPU limitations while improving data movement efficiency and reducing latency in data center workloads. XCENA’s architecture is designed to support applications such as artificial intelligence workloads, vector databases, and large-scale analytics by addressing memory bandwidth and capacity constraints. The company provides a hardware-software ecosystem that includes computational memory systems and a full-stack software development kit. This SDK offers APIs, runtime tools, and drivers that allow applications to use computational memory without major changes to existing software architectures while also supporting low-level control for performance optimization.XCENA’s flagship product line includes MX1, a CXL-based computational memory solution that integrates near-data processing engines with memory infrastructure to support AI inference and data-intensive workloads. The platform is designed to improve throughput and scalability in environments where traditional memory architectures become a bottleneck. The company operates in the broader field of AI infrastructure and memory innovation, working with customers such as hyperscalers, telecom providers, and research institutions that manage large-scale computing workloads. Its solutions are intended to improve efficiency in systems handling AI, big data processing, and scientific computing. | $44M / Series A / May 13, 2024 | |
Plcoskin
|
Plcoskin is a MedTech company specializing in reconstructive plastic surgery and regenerative skincare. They have developed a scaffold that removes the need for cadaver-sourced material used in breast reconstruction surgery, making procedures safer and cheaper. Plcoskin’s scaffolds are made with synthetic PCL, a biodegradable material that iscommonly used to create surgical sutures. Unlike competitors' products that remain in the body for a lifetime, Plcoskin’s PCL scaffolds are absorbed and replaced with the recipient’s own natural tissues, minimizing the possibility of long-term side effects. As they do not contain any dangerous chemicals, they are also 50% safer than cadaver-sourced scaffolds.Costs for reconstructive breast surgery are brought down by 40% to only $3 thousand per breast. Furthermore, much less handling time is required, reducing average surgery durations from an hour and a half to only 30 minutes. The mesh design of the scaffolds mitigates the need for an additional follow-up reconstructive surgery, something that is common when using cadaver-sourced scaffolds.Plcoskin has also developed Youlief, a cosmeceutical product & therapeutic device pipeline that helps fund R&D for their medical devices. Youlief is available in the US, Europe, Taiwan, Singapore and Japan. | $4M / Series B / Aug 31, 2023 | |
S-Alpha Therapeutics
|
S-Alpha Therapeutics is a digital health company developing software-based therapeutic solutions by combining biotechnology and IT. It focuses on digital therapeutics for conditions such as pediatric myopia and other unmet medical needs. The company builds clinically validated SaMD products, collaborates with global partners, and advances AI-drivenhealthcare solutions to transform treatment approaches. | $8.4M / Series B / Mar 15, 2023 | |
| See all 29 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does TONY Investment invest in?
TONY Investment invests primarily in Biotechnology, Health Care and Manufacturing startups, most often at Series A and Series B stage. Most of the 29 investments tracked by Shizune back companies in South Korea. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is TONY Investment's check size?
TONY Investment typically joins rounds of $3M–$15M at Seed, $2.9M–$63M at Series A and $4M–$22M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds TONY Investment participates in.
How do I contact TONY Investment?
Public channels for TONY Investment include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at TONY Investment?
The team at TONY Investment includes Joowon Park (Managing Director). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
